Mark For: RIABNI® trademark registration is intended to cover the categories of
Research | OneLook Acronym Finder |
Serial Number | 88182290 |
Registration Number | 6809212 |
Mark Literal Elements | RIABNI |
Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
Mark Type | TRADEMARK |
Register | PRINCIPAL |
Current Location | INTENT TO USE SECTION 2019-11-05 |
Basis | 1(b) |
Class Status | ACTIVE |
Primary US Classes |
|
Primary International Class |
|
Filed Use | No |
Current Use | No |
Intent To Use | Yes |
Filed ITU | Yes |
44D Filed | No |
44E Current | No |
66A Current | No |
Current Basis | No |
No Basis | No |
Attorney Name | Timothy J. Gaul |
Law Office Assigned | L80 |
Employee Name | BUSH, KAREN K |
2018-11-05 | Application Filed |
2019-09-10 | Published |
2019-09-10 | Published for Opposition |
2019-11-05 | Location: INTENT TO USE SECTION |
2019-11-05 | Status: Live/Pending |
2019-11-05 | Transaction Date |
2021-04-05 | Status: A third request for extension of time to file a Statement of Use has been granted. |
2022-08-02 | Trademark Registered |
Party: | Amgen Inc. |
Address | Trademark Operations - MS-28-5A One Amgen Center Drive Thousand Oaks, CALIFORNIA UNITED STATES 913201799 |
Legal Entity Type | Corporation |
Legal Entity State | DELAWARE |
Drawing | JPEG | 2018-11-05 |
TEAS RF New Application | MULTI | 2018-11-05 |
XSearch Search Summary | XML | 2018-12-12 |
Notation to File | XML | 2018-12-13 |
Priority Action | XML | 2018-12-13 |
TEAS Rev, App and/or COA of Atty/Dom.Rep | XML | 2019-03-07 |
Examiners Amendment | XML | 2019-07-25 |
Amendment and Mail Process Complete | MULTI | 2019-07-26 |
TRAM Snapshot of App at Pub for Oppostn | MULTI | 2019-07-30 |
Notice of Publication | XML | 2019-08-21 |
Notification Of Notice of Publication | XML | 2019-08-21 |
OG Publication Confirmation | XML | 2019-09-10 |
Notice of Allowance | XML | 2019-11-05 |
Extension of Time to File SOU | XML | 2020-04-28 |
ITU Extension Approval | XML | 2020-04-30 |
ITU Unit Action | MULTI | 2020-04-30 |
Extension of Time to File SOU | XML | 2020-10-29 |
ITU Extension Approval | XML | 2020-10-31 |
ITU Unit Action | MULTI | 2020-11-02 |
Extension of Time to File SOU | XML | 2021-04-05 |
ITU Extension Approval | XML | 2021-04-07 |
ITU Unit Action | MULTI | 2021-04-07 |
Change Address or Representation Form | XML | 2021-05-06 |
IC 005. US 006 018 044 046 051 052. G & S: Pharmaceutical preparations for treatment of oncologic, inflammatory and auto-immune diseases and disorders; pharmaceutical preparations for treatment of arthritis; pharmaceutical preparations for treatment of diseases and disorders of the blood, skin, bone marrow, nervous system, immune system and joints; pharmaceutical preparations for treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), pemphigus vulgaris (PV), multiple sclerosis (MS), and stem cell transplantation
International Codes: | 5 |
U.S. Codes: | 006,018,044,046,051,052 |
Type Code | Type |
---|---|
GS0051 | Pharmaceutical preparations for treatment of oncologic, inflammatory and auto-immune diseases and disorders; pharmaceutical preparations for treatment of arthritis; pharmaceutical preparations for treatment of diseases and disorders of the blood, skin, bone marrow, nervous system, immune system and joints; pharmaceutical preparations for treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), pemphigus vulgaris (PV), multiple sclerosis (MS), and stem cell transplantation |
GS0051 | Pharmaceutical preparations for treatment of inflammatory and auto-immune diseases and disorders; pharmaceutical preparations for treatment of arthritis; pharmaceutical preparations for treatment of diseases and disorders of the immune system and joints; pharmaceutical preparations for treatment of non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA) |
Description | Date | Proceeding Number |
---|---|---|
TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS | 2021-05-06 | |
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2021-05-06 | |
TEAS CHANGE OF CORRESPONDENCE RECEIVED | 2021-05-06 | |
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2021-05-06 | |
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2021-04-07 | |
TEAS EXTENSION RECEIVED | 2021-04-05 | |
EXTENSION 3 GRANTED | 2021-04-05 | 98765 |
EXTENSION 3 FILED | 2021-04-05 | 98765 |
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2020-10-31 | |
TEAS EXTENSION RECEIVED | 2020-10-29 | |
EXTENSION 2 GRANTED | 2020-10-29 | 98765 |
EXTENSION 2 FILED | 2020-10-29 | 98765 |
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | 2020-04-30 | |
TEAS EXTENSION RECEIVED | 2020-04-28 | |
EXTENSION 1 GRANTED | 2020-04-28 | 98765 |
EXTENSION 1 FILED | 2020-04-28 | 98765 |
NOA E-MAILED - SOU REQUIRED FROM APPLICANT | 2019-11-05 | |
PUBLISHED FOR OPPOSITION | 2019-09-10 | |
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | 2019-09-10 | |
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | 2019-08-21 | |
ASSIGNED TO LIE | 2019-08-08 | 70633 |
APPROVED FOR PUB - PRINCIPAL REGISTER | 2019-07-29 | |
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | 2019-07-25 | 6328 |
EXAMINERS AMENDMENT E-MAILED | 2019-07-25 | 6328 |
EXAMINERS AMENDMENT -WRITTEN | 2019-07-25 | 67516 |
EXAMINER'S AMENDMENT ENTERED | 2019-07-25 | 88888 |
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | 2019-03-07 | |
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | 2019-03-07 | |
PRIORITY ACTION WRITTEN | 2018-12-13 | 67516 |
PRIORITY ACTION E-MAILED | 2018-12-13 | 6326 |
NOTIFICATION OF PRIORITY ACTION E-MAILED | 2018-12-13 | 6326 |
ASSIGNED TO EXAMINER | 2018-12-11 | 67516 |
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM | 2018-11-20 | |
NEW APPLICATION ENTERED IN TRAM | 2018-11-08 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.